Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BRC
1 Momentum Stock on Our Buy List and 2 We Turn Down StockStory - Sun Aug 16, 11:40PM CDT

1 Momentum Stock on Our Buy List and 2 We Turn Down

BRC : 92.01 (-2.28%)
CATY : 62.51 (-2.63%)
BMY : 67.61 (+2.36%)
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Business Wire - Thu Aug 13, 4:12PM CDT

Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory...

BMY : 67.61 (+2.36%)
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PR Newswire - Thu Aug 13, 7:00AM CDT

SAN DIEGO , Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics...

RNA : 13.71 (+6.78%)
BMY : 67.61 (+2.36%)
A trader celebrating success by Tima Miroshnichenko via Pexels
Redwire Takes Off on Solid Q2 Results. How to Play RDW Stock Here. Barchart - Mon Aug 10, 9:57AM CDT

The space company reported record revenues and a double beat, and its potential looks astronomical.

RDW : 12.40 (-4.17%)
SPCX : 139.65 (-2.57%)
BMY : 67.61 (+2.36%)
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas Business Wire - Mon Aug 10, 8:01AM CDT

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS’ $40 Billion Commitment...

BMY : 67.61 (+2.36%)
WWW
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid StockStory - Sun Aug 9, 11:38PM CDT

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

JKHY : 163.06 (+6.49%)
WWW : 20.85 (+4.30%)
BMY : 67.61 (+2.36%)
BMY
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions StockStory - Thu Aug 6, 12:46AM CDT

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

BMY : 67.61 (+2.36%)
Bristol Myers Squibb logo under a magnifying glass_ By Casimiro
The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today Barchart - Mon Aug 3, 3:54PM CDT

Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.

AZN : 164.95 (+3.03%)
BMY : 67.61 (+2.36%)
Trader 2 at NYSE by Orhan Akkurt via Shutterstock
Stocks Set to Open Higher as Oil Sinks on U.S.-Iran Deal Hopes, Jobs Data and Earnings Awaited Barchart - Mon Aug 3, 5:30AM CDT

September S&P 500 E-Mini futures (ESU26) are up +0.57%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.47% this morning, pointing to a higher open on Wall Street as oil prices sank after U.S....

GOOGL : 344.72 (+0.15%)
UAL : 115.78 (-2.48%)
AAPL : 316.83 (+2.19%)
SNDK : 1,568.87 (-3.50%)
NQU26 : 29,618.00 (+0.36%)
PFE : 28.24 (+3.63%)
SHOP : 146.58 (unch)
MSFT : 484.31 (+0.56%)
TSLA : 351.12 (+4.23%)
FERG : 243.19 (-0.52%)
WDC : 462.09 (-6.87%)
ESU26 : 7,738.50 (+0.12%)
BMY
BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook StockStory - Fri Jul 31, 12:36AM CDT

BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook

BMY : 67.61 (+2.36%)

Barchart Exclusives

Forced Out of $5.6B in Sandisk, Leopold’s Bull Case Is Still Alive. Here’s How You Should Play It. Barchart - 1 hour ago
Sandisk's brutal July selloff was amplified by a forced hedge-fund unwind, but its latest results and long-term contracts suggest the underlying business is getting stronger and more predictable. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.